Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

CFRA analyst Wan Nurhayati revised the price target for GlaxoSmithKline (NYSE:GSK) shares, reducing it to $40.00 from the ...

UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.80. The company’s ...

In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price ...

Annual core operating profit increased in 2024 for British pharmaceutical company GSK compared to 2023, the company reported ...

GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...

Matthew Moll, MD, MPH, and Michael H. Cho, MD, MPH, from the Department of Medicine at Brigham and Women's Hospital are ...

Learn more about whether Arrowhead Pharmaceuticals, Inc. or Veracyte, Inc. is a better investment based on AAII's A+ Investor ...

Dynavax should take a leaf from its vaccine maker peer, Novavax, and work to monetize its CpG1018 adjuvant. Learn more about ...

The biggest fallers on the FTSE 100 were Diageo, down 92.5p to 2235p, DCC, down 195p to 5300p, Croda, down 103p to 3110p, ...

Advertisers are turning to creative strategies to capture attention ahead of the showdown between the Philadelphia Eagles and ...

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...